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Until  the  past  two decades,  almost  all colorectal  polyps  were  divided  into  two  main  groups:  hyperplas-
tic  polyps  and  adenomas.  Sessile  serrated  adenomas  presented  endoscopic,  pathological  and  molecular
proﬁles  distinct  from  others  polyps.  Previously  under-diagnosed,  physicians  now  identiﬁed  sessile  ser-
rated  adenomas.  The  serrated  neoplastic  pathway  is  accounting  for up  to  one-third  of  all  sporadic
colorectal  cancers  and  sessile  serrated  adenomas  have  been  identiﬁed  as the  main  precursor  lesions  in
serrated  carcinogenesis.  By  analogy  with  the  adenoma–adenocarcinoma  sequence,  the  sessile  serrated
adenomas–adenocarcinoma  sequence,  has  been  identiﬁed.  The  development  of endoscopic  resection
techniques  permits  the  consideration  of  a non-surgical  approach  as  the  ﬁrst  option  regardless  of theolecular pathology
errated  adenoma
size  of the  lesion.  Sessile  serrated  adenoma  warrants  the  watchfulness  of  physicians  and  requires  an
optimal  quality  of  the  colonoscopy  procedure,  a  thorough  evaluation  of  the lesion,  an  adequate  endo-
scopic  resection  and  follow-up  colonoscopies  in accordance  with  sessile  serrated  adenomas  guidelines.
We  herein  present  a  review  on  sessile  serrated  adenomas  focusing  on  their pathological  speciﬁcities,
epidemiology,  treatment  modalities  and  follow-up.
©  2014  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  
ND lic. Introduction
Until the past two decades, almost all colorectal polyps were
ivided into two main groups: hyperplastic polyps and adenomas.
yperplastic polyps constitute a very common type in western
opulation with an estimated prevalence of 20%, accounting for
ne-third of all resected polyps. Hyperplastic polyps are character-
zed by their “saw-tooth” appearance on microscopy analysis from
he folding in of the crypt epithelium. Colorectal adenomas have
een identiﬁed as a pre-neoplastic lesion following the adenoma
 colorectal cancer sequence [1,2]. This ﬁnding justiﬁed colorec-
al cancer screening programmes leading to the resection of all
denomas in order to reduce colorectal cancer incidence [3].
In  1990, Longacre and Fenoglio-Preiser noticed that some “ser-
Open access under CC BY-NC-ated” polyps shared features with both conventional adenomas
nd hyperplastic polyps, and thereby coined these polyps “tradi-
ional serrated adenomas” [4]. In 1996, Torlakovic et al. identiﬁed
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displaying an abnormal architecture without cytological dysplasia
and deﬁned them as “sessile serrated adenomas” (SSAs), which are
now considered as precursors of microsatellite unstable colorectal
carcinomas [5,6]. The prevalence of SSAs has been underestimated
for years, ranging from 0.1% to 14.7% of all colorectal polyps [7,8].
The deﬁnition of this new entity requires particular attention and
SSAs should be differentiated from conventional colorectal ade-
nomas. We herein present a review on SSAs focusing on their
pathological speciﬁcities, epidemiology, treatment and follow-up
modalities.
2. Histological and bio-molecular features
2.1. Histological architecture
Serrated  polyps are divided into three main categories using the
WHO classiﬁcation of tumours of the digestive system [9]: typi-
cal hyperplastic polyps, SSAs and traditional serrated adenomas. In
ense.this classiﬁcation, SSA and “sessile serrated polyp” are synonymous
terms and both are acceptable diagnostic terms. Histological diag-
nostic criteria of serrated lesions are presented in Table 1. As all
serrated lesions, SSAs are characterized by their jagged appearance
en access under CC BY-NC-ND license.
96 B. Bordac¸ ahar et al. / Digestive and Liver Disease 47 (2015) 95–102
serrat
o
t
i
d
p
I
i
a
f
t
ﬁ
a
c
f
l
h
s
t
a
t
p
i
t
c
T
TFig. 1. Histological features of sessile 
n microscopy analysis. They display a larger size than hyperplas-
ic polyps and mostly occur in the proximal colon. The diagnosis
s based mainly on architectural features with a disorganized and
istorted crypt growth pattern. Major differences between hyper-
lastic polyps and SSAs concern the basal portion of the polyp.
ndeed, the serrations affect the entire length of the crypt, bottom
ncluded for sessile serrated adenoma/polyp (Fig. 1A). Crypt bases
ppear dilated or irregularly branched, with horizontal extension
orming an “L” or inverted “T” shape, unlike other serrated lesions
hat do not display an abnormal architecture in that area. These
ndings demonstrate that hyperplastic polyps and sessile serrated
denoma/polyps are difﬁcult to distinguish from one another in
ase of superﬁcial biopsies or electrocautery artefacts resulting
rom endoscopic resection [10].
SSAs crypts tend to arrange themselves parallel to the muscu-
aris mucosa and sometimes even beneath this layer thus achieving
erniation through it (Fig. 1B). They are lined with columnar
ecreting clariﬁed cells, and generally less eosinophil cells in
raditional serrated adenoma than in adenoma. Mature goblet
nd mucinous cells are found within the base of the crypts and
rigger excessive mucous production which often results in the
resence of mucin in the lumen of dilated crypts. Such character-
stics are not observed in hyperplastic polyps where the lowest
hird of the crypts remain narrow and lined with proliferative
ells.
able 1
ypes of serrated lesions and their histological features.
Types of serrated lesions Histological features
Hyperplastic polyps (goblet
cell,  microvesicular and
mucinous  poor-hyperplastic
polyps)
•  Local mucosal thickening
•  Serration more pronounced in the
upper half of the crypts
•  Linear and straight crypts without
distortion
• Epithelium lined with different cells
(microvesicular mucinous, goblet or
undifferentiated) depending on
variants of hyperplastic polyps
Traditional serrated adenoma • Eosinophilic cytoplasm and
elongated nuclei
•  Crypt budding
•  Distorted villous or tubulo-villous
architecture
Sessile  serrated adenoma • Dilated and/or branched crypts
• Saw-tooth appearance involves the
entire length of the crypt, including
crypt base
•  Horizontal extension of crypt bases
• Herniation of crypts through the
muscularis mucosa
•  Cytological dysplasia is mostly
missinged adenomas on microscopy analysis.
SSAs may  harbour cytoplasmic and nuclear atypia with features
similar to both low-grade and high-grade dysplasia in conven-
tional adenomas, which is considered as an indicator of a higher
risk of rapid progression to colorectal cancer [11]. SSAs have been
under-diagnosed by pathologists and often wrongly considered
as hyperplastic polyps as illustrated by a recent study from Gill
et al. in which three pathologists blinded to the original diagno-
sis re-examined the slides of all right sided polyps ﬁrst labelled as
hyperplastic polyps and re-classiﬁed 30–64% of them as SSAs [12].
According to the American Gastroenterology Association, only
one crypt showing the characteristic features is sufﬁcient for the
diagnosis of SSA while in the WHO  classiﬁcation at least three crypts
(or two adjacent crypts) should be present for the diagnosis [13].
This discrepancy induces a signiﬁcant impact on SSA prevalence [7].
With a strict application of the diagnostic criteria outlined in the
last edition (2010) of the WHO  classiﬁcation, Bettington et al. iden-
tiﬁed that SSAs represented 12.1% of all polyps [7]. The incidence
raised to 14.7% applying criteria of the American Gastroenterology
Association.
The third category of serrated polyp corresponds to the
traditional serrated adenoma. It usually shows a protuberant exo-
phytic conﬁguration, complex villous growth architecture and
an abundance of columnar cells with eosinophilic cytoplasms. A
characteristic pattern of budding of proliferative crypts situated
perpendicular to the long axis of villous structures is frequently
observed. Both conventional adenoma-like dysplasia and serrated
dysplasia can be encountered in traditional serrated adenomas. The
overall prevalence of traditional serrated adenoma and SSAs was
0.6% and 2.3%, respectively [14].
Due to terminology problems and histologic overlap among the
features of these different serrated lesions, pathologists encounter-
some difﬁculties in classifying some lesions. However, few studies
have evaluated the reproducibility of light microscopic diagnosis
of serrated polyps among pathologists and reported a moderate to
good agreement for polyp classiﬁcation ( = 0.56–0.63) [15,16].
2.2. Serrated neoplastic pathway
In contrast with the adenoma – adenocarcinoma sequence
occurring through chromosomal instability, responsible for pro-
gressive accumulation of mutations in oncogenes and tumour-
suppressor genes, the serrated neoplastic pathway is characterized
by aberrant methylation in promoter regions of speciﬁc genes.
This epigenetic mechanism is based on hyper-methylation within
sequences of pairs of cytosine and guanine nucleotides, called CpG
islands, found in promoter regions of genes. These alterations result
in the “CpG islands methylator phenotype” (CIMP) at either low or
high degree which reduces gene expression without altering the
DNA sequence. Hyper-methylation may  occur in DNA mismatch
repair gene (MMR)  hMLH-1 associated with the development of
 and Liver Disease 47 (2015) 95–102 97
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Table 2
Endoscopic appearance of sessile serrated adenomas.
Location Preferentially located in the proximal colon
Size Generally larger than 10 mm
Shape Flat O-IIaa or O-IIba
Sessile O-Isa
Edges Hardly distinguishable using white light endoscopy
Lateral borders identiﬁed using chromoendoscopy
Colour Similar to surrounding colonic mucosa
Often covered by stools or bile salts giving a yellow or green
“mucus  cap”
Pit  patterns Type  II-O +++
Type  III-SA and IV-SAB. Bordac¸ ahar et al. / Digestive
icrosatellite unstable (MSI) cancer. Whereas MSI  cancers arising
rom Lynch syndrome have been clearly linked to germline muta-
ions in genes of DNA MMR  system (hMLH-1, hMSH-2, hMSH-6),
SI cancers occurring in the course of the serrated pathway are
ue to a loss of function within DNA MMR  system by promoter
yper-methylation of hMLH-1 only. Hawkins and Ward showed
hat all serrated polyps diagnosed in patients with sporadic MSI
ancers exhibited hMLH-1 promoter hyper-methylation [17]. SSAs
n which hMLH-1 expression is still effective may  evolve through
-Raf mutation and CIMP-high to microsatellite stability status can-
ers.
The other main molecular feature of SSAs concerns the status of
-Raf. Spring et al. showed in a prospective study that SSAs were
ighly associated with B-Raf “V600E” mutation (nearly 80%) [18].
his ﬁnding was further validated by the work of Carr et al. which
evealed a proportion of 90% of SSAs exhibiting a B-Raf mutation
19]. It is important to stress that SSAs share this molecular feature
ith microvesicular-hyperplastic polyps which have led Yang et al.
o suggest that SSAs may  have evolved from this type of hyperplas-
ic polyps [20].
Moreover, B-Raf mutation is strongly linked with CIMP-high
SAs or sporadic MSI-high colorectal cancers, as shown by Kam-
ara et al. [21]. Despite most biomolecular features of SSAs having
een solved, the chronology of events along the serrated pathway
emains uncertain. As B-Raf mutation and CIMP have been iden-
iﬁed in the earliest serrated lesions (microvesicular-hyperplastic
olyps,  SSAs without dysplasia) they are presumed by experts to
e the initial stages of the serrated pathway [13]. The loss of func-
ion of hMLH-1 through hyper-methylation of its promoter region
s thought to be a later event along this sequence with a higher
isk of progression to cancer as suggested by the strong preva-
ence of hMLH-1 methylation in SSAs with cytological dysplasia
22–24].
In a very recent study, Gala et al. showed that germline muta-
ions in genes involved in senescence pathways were associated
ith the development of multiple SSAs [25]. In particular, they
dentiﬁed nonsense mutations in RF43, known to be implicated in
he regulation of the DNA damage response in patients with sessile
errated polyposis syndrome described below.
The molecular features of the TSA traditional serrated adenoma
re less well established but include K-RAS mutations and aber-
ant methylation with hypermethylation of the promoter of MGMT
methylguanine DNA methyltransferase) [26]. The TSA traditional
errated adenomas have clearly much lower B-Raf mutation fre-
uency than sessile serrated adenomas/polyp.
In summary, serrated pathway has recently emerged as the sec-
nd pathway leading to colorectal cancer, therefore, the genetic
lterations occurring in this pathway are not clariﬁed and there is
reat variability in the frequency of molecular changes described.
pproximately, 10% of sporadic colorectal cancers arise via serrated
olyp-carcinoma sequence: microvesicular hyperplastic polyp
rogress to sessile serrated adenoma/polyp, sessile serrated ade-
oma polyp with cytologic atypia and then to colorectal carcinoma.
-Raf V600E mutation is an early event in the serrated neoplasia
athway, mostly present in sessile serrated adenoma/polyp, lead-
ng to the development of MSI  colonic carcinomas.
. Endoscopic features
SSAs  are commonly located in the proximal colon (right colon
nd caecum) and are associated with female sex and smok-
ng [27,28]. Anderson et al. pointed out that the relative risk
f large SSAs, over 1 cm,  was up to 10.2 in smokers compared
o non-smoking patients [29]. The prevalence of SSA has been
stimated from 1% to 16% of colonoscopies [30–33]. First hypoth-
sis for such discrepancies was an insufﬁcient identiﬁcation ofO, open shape; SA, serrated adenoma.
a Following the Paris classiﬁcation.
SSAs by gastroenterologists and SSAs diagnosed as hyperplas-
tic polyps by pathologists [12,34]. In recent years though, the
development of high-deﬁnition endoscopes, chromo-endoscopy
and quality criteria for colonoscopy resulted in a higher identi-
ﬁcation rate of serrated lesions; in the meantime, pathologists
agreed on diagnostic criteria for SSAs. The ever growing adenoma
detection rate is related to the increasing skills of physicians per-
forming colonoscopy and is now identiﬁed as quality criteria for
colonoscopy as well as bowel preparation and withdrawal time
[30,35–37]. Burnett-Hartman et al. pointed out that patients who
had undergone previous colonoscopy examination did not have a
reduced risk for SSA [38]. One aspect of SSA is to be ﬂat and their
ability to ﬁx stools or bile salts to their wall due to mucins hyper
secretion, including mucins 1 and 4 [39] (Fig. 2). This speciﬁcity
reinforces the usefulness of a complete exploration of the colon
using high deﬁnition endoscopes with optimal bowel preparation
before colonoscopy to avoid missed lesions [33,34]. It has been sug-
gested that an 8% serrated- and 25% adenoma-detection rate should
be a criterion of a high quality colonoscopy [40,41].
The increasing quality of the colonoscopy procedure has led
to the endoscopic identiﬁcation of lesions suggesting SSAs. The
features of SSAs, in the shape of the adhesion of bile salts and
stools, display to certain extent speciﬁcity but SSAs may  also
mimic  adenomatous or hyperplastic lesions. SSAs appear ﬂat or
slightly elevated and are commonly larger than 10 mm.  The use of a
high deﬁnition endoscope and indigo-carmine chromo-endoscopy
is associated with a higher detection rate of serrated adenomas,
reaching 16% [42]. Virtual chromo-endoscopy using narrow band
imaging increases the number of colonic lesions identiﬁed but does
not impact the SSA detection rate. Meanwhile, in one-third of cases,
lesions considered as SSA under virtual chromoendoscopy appear
as hyperplastic polyps on pathological examination [43]. Magnify-
ing endoscopy enables the identiﬁcation of the pit pattern of SSAs,
which generally corresponds to types II, III-L or IV (Table 2) [34].
Morita et al. modiﬁed Kudo’s pit pattern classiﬁcation to differenti-
ate SSAs from hyperplastic polyps (corresponding to Kudo type II)
creating type III-SA and type IV-SA [44]. A type III-SA polyp displays
elongated oval and stellar-like crypt oriﬁces and a type IV-SA lesion
pineal or ﬂower petal-like form. A pit pattern type II-O described
by Kimura et al., was developed to endoscopically identify SSAs
through open-shaped pit pattern [45] (Fig. 3). Lesions identiﬁed
as type II-O considering their morphological features were SSAs
with a 84–97% speciﬁcity and 65–86% sensitivity [45,46]. The dis-
tinction between normal and pathological mucosa is difﬁcult using
white light endoscope and justiﬁes the use of chromoendoscopy.
Furthermore, indigo carmine chromo-endoscopy appears to be a
useful tool for both identiﬁcation and size assessment of SSAs and
thus can help physicians in endoscopic resection [42].
SSAs  are commonly located in the proximal colon and justify
an optimal quality of the colonoscopy procedure to identify all
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esions. Serrated polyposis syndrome should be kept in mind in
ase of multiple SSAs. This syndrome, previously entitled hyper-
lastic polyposis syndrome is associated with an enhanced risk of
olorectal carcinoma [47–49]. According to the WHO  classiﬁcation,
hree criteria are required for the diagnosis of the serrated polypo-
is syndrome: (i) more than four serrated polyps above the sigmoid
olon with two or more larger than 10 mm;  (ii) any number of ser-
ated polyps proximal to the sigmoid colon in a patient who  had
 ﬁrst-degree relative with this syndrome; (ii) more than 20 ser-
ated polyps of any size anywhere in the colon. Serrated polyposis
yndrome diagnosis is made if any of the three criteria is present.
he knowledge of this syndrome is of interest since the WHO
lassiﬁcation recommended colonoscopy surveillance every single
ear.
. Treatment
.1. Endoscopic resection
The  colonoscopy has been validated as the gold standard proce-
ure for the diagnosis of colorectal neoplasms [50]. It also allows
o resect pre-neoplastic lesions, which reduces the incidence of
olorectal cancer and thus the rate of deaths resulting from it [3].
onsidering SSAs, all identiﬁed lesions regardless of their size in
he proximal sigmoid or larger than 5 mm  in the recto-sigmoid,
hould be removed [13]. Complete resection of recto-sigmoid SSAs
maller than 5 mm is deemed unnecessary and only sampling for
istological study should be performed.
SSAs are typically ﬂat and sessile lesions, with hardly dis-
inguishable borders. After a submucosal injection is performed,
he lesions tend to increase in size and their limits are even
arder to identify (Fig. 3). Thus, when a SSA is suspected, the
revention of post-polypectomy bleeding by adding epinephrine
o the indigo stained saline solution used for submucosal injec-ht endoscopy (A and C), and virtual chromoendoscopy using Narrow Band Imaging
tion  is not recommended, since the subsequent whitening of the
mucosa makes the lesion almost impossible to see (unpublished
data). SSA endoscopic resection results in a higher incomplete
resection rate (30%) compared with adenomas (10%), mainly due
to positive lateral margins [51]. The risk of incomplete resection
increases with the size of SSA. It appeared important to mix saline
with carmine indigo to better evaluate the lateral margins of
SSA and increased the complete resection rate. Therefore, a thor-
ough assessment of the lesion including morphology, pit pattern,
borders, and possible other lesions in the colonic segment is essen-
tial: (i) to identify invasive cancer (Kudo type V) or countless
lesions requiring surgical resection (ii) to guide the choice of the
endoscopic resection technique, in order to prevent incomplete
resection and recurrence. The use of high deﬁnition endoscopes,
zoom or magniﬁcation endoscopy, indigo carmine dye spraying
chromo-endoscopy or virtual chromo-endoscopy, either, Narrow
band Imaging (NBI, OlympusTM), Fujinon Intelligent Computed
Endoscopy (FICE, FujinonTM), or image enhancement techniques
(I-Scan, PentaxTM), might be useful tools during the identiﬁcation
procedure.
The endoscopic resection techniques for SSAs are similar to any
other polyp resection in the proximal colon. For diminutive lesions
(≤5 mm)  cold snare should be preferred to forceps biopsy polypec-
tomy [52]. For small (<10 mm)  SSAs, endoscopic resection using
a cold snare is feasible and safe, as well as conventional endo-
scopic mucosal resection (EMR) [53]. For larger SSAs, the choice of
resection techniques depends on the size of the lesion, its location,
its shape and the skills of the endoscopist. Given its technical sim-
plicity, conventional EMR  is the appropriate treatment for <20 mm
lesions, which can be resected en bloc. In a retrospective review of
226 SSAs with a mean size of 8 mm (2–40), Gurudu et al. reported
that 97.3% of these lesions were amenable to EMR, without proce-
dure related complications [54]. For sessile colorectal polyps above
20 mm,  no speciﬁc data is available for SSAs. Piecemeal EMR  has
B. Bordac¸ ahar et al. / Digestive and Liver Disease 47 (2015) 95–102 99
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aig. 3. Endoscopic images of a serrated adenoma. High deﬁnition white light endos
fter  ﬂushing (B); vascular and mucosal pattern under Blue Laser Imaging (Lasereo
aser  Imaging and two  levels of zoom (E and F).
ong been shown to be safe and feasible with a 5.3% overall compli-
ation rate [55]. These complications are mainly colonic perforation
0.6–4.4%) and delayed bleeding (2.9–7.7%) [56–58].
Endoscopic submucosal dissection (ESD) is an option for
esection of colonic neoplasms in expert centres. It allows for en
loc, carcinologic resection of lesions with no or low risk of lymph
ode involvement, i.e. adenomas with low and high-grade dyspla-
ia and adenocarcinomas with an <1000 m inﬁltration of the sub-
ucosa [59]. Thus, recurrence rates are much lower after ESD than
fter piecemeal EMR  [60]. However, this procedure is technicallytypical presentation of a right sided serrated adenoma covered with mucus (A) and
on), either standard (C) or bright mode (D); endomicroscopic analysis using Blue
challenging,  time consuming, and carries a high rate of complica-
tions, especially with a 6–7% rate of colonic perforations [60,61].
Thus, ESD cannot be recommended in 2014 as a routine treat-
ment for large SSAs, especially since their malignancy is limited.
Piecemeal EMR  is very often done since the incidence of car-
cinoma involving the submucosa associated with SSA is very
low. Hybrid or simpliﬁed ESD is a recently developed endoscopic
resection modality in which a peripheral mucosal incision is per-
formed around the lesion to create a groove and improve the
engagement of a polypectomy snare. It allows en bloc resection of
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arge lesions without reaching the morbidity of conventional ESD
62]. Hybrid ESD might become the treatment of choice for large
SAs.
Given the higher frequency of delayed bleeding of polyps located
n the right colon, the closure of the mucosectomy scar using hemo-
lips is recommended, and allows for safe ambulatory management
f patients, even after large EMR  [55,56].
.2. Surgery
Surgery is warranted in case of invasive sessile serrated carci-
oma or serrated polyposis syndrome, in order to prevent the risk
f progression to colorectal cancer [63]. It also appears to be the
econd best option and when endoscopic resection is likely to fail,
s in cases of lesions reaching the appendix and the ileocaecal valve,
r when endoscopic resection does not seem feasible given the size
f SSA. Partial colectomy can ﬁnally be considered in case of itera-
ive recurrences of SSAs, even if most recurrences can be managed
ndoscopically.
. Cancer risk and recommendations
.1.  Cancer risk assessment
Colorectal  risk assessment among patients with SSAs takes
nto account the number, location, size and histologic features
f the polyps. The presence of large serrated polyps is strongly
ssociated with advanced neoplasia and colorectal cancer [64].
arge (>10 mm)  serrated polyps are independently associated withensus [13] (), the European Society of Gastroenterology () [74] and the American
synchronous advanced colorectal neoplasia with a 3.24 odds ratio
risk [65]. The detection of at least one proximal non-dysplastic ser-
rated polyp during a screening colonoscopy is associated with an
increased risk of synchronous advanced neoplasia (odds ratio = 1.9)
[66]. Its association is also stronger for large, more than 1 cm,  non-
dysplastic serrated polyps with a 3.37 odds ratio risk. Patients with
advanced neoplasia and non-dysplastic proximal serrated polyp
at baseline examination double their risk of an interval neoplasia
colorectal cancer during surveillance [66].
Patients with SSAs and no history of either colorectal cancer or
adenomatous polyp may  develop colorectal cancer during follow-
up [67]. A relatively slow progression from SSAs to carcinoma over
10–15 years has been identiﬁed in a large serie [68]. Its evolu-
tion, longer than the adenoma–adenocarcinoma sequence might
explain the 1% incidence rate of colorectal carcinoma or high grade
dysplasia observed in retrieved SSAs.
The lifetime risk for colorectal cancer for patients with serrated
polyposis syndrome is up to 50% for colorectal cancers [47,69,70].
In patients with a serrated polyposis syndrome a 7% cumulative risk
of cancer at 5 years has been suggested [71]. Relatives have to be
screened considering that ﬁrst-degree relatives of serrated polypo-
sis syndrome patient have an increased relative risk of colorectal
cancer ≥5 [71,72].
5.2.  Monitoring recommendationsThe  role of serrated polyps in colon carcinogenesis has been
highlighted and the United States Multi-Society Task Force has
raised some recommendations’ for SSAs’ colonoscopy surveillance
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fter screening and polypectomy [73]. Recommendations for inter-
al follow-up have been based on size, location and the existence or
ot of a dysplasia. Thus, patients with small SSAs, less than 10 mm,
nd without dysplasia should be managed like “low-risk adeno-
as” and followed-up at 5 years. It is recommended that patients
ith large SSAs, larger than 10 mm or with cytological dysplasia be
anaged like “high-risk” adenomas and repeat colonoscopy should
e performed in 3 years. The United States recommendations for
SA’ colonoscopy surveillance are in line with European Society of
astrointestinal Endoscopy [74]. As the signiﬁcance of the grade of
ysplasia has not been clearly evaluated in SSAs, it has been sug-
ested by experts that SSA with any cytological dysplasia should
e considered as an “advanced” polyp, equivalent to an high-grade
ysplasia observed in conventional adenomas [13]. Therefore, the
ifference between guidelines and experts consensus does exist
nd is that the latter recommend to shorten the surveillance from
 to 1 years depending on the dysplasia SSAs while the guidelines
roposed a 3 years follow-up [13,73]. An algorithm of surveillance
fter resection of SSAs adapted from guidelines is proposed in Fig. 4
13,73,74]. The French health authority, HAS (Haute Autorité de
anté), edited some recommendations on SSA’ surveillance based
n the United Kingdom, United States and European recommen-
ations [73,75]. They recommended in cases of high risk SSA a
ontrolled colonoscopy at 3 years.
A surveillance colonoscopy per year for patients with serrated
olyposis syndrome should be performed. For patients with a fam-
ly history of serrated polyposis syndrome, experts suggested that
rst-degree relatives should be screened with colonoscopy at 40
ears of age or 10 years younger than the age at diagnosis of the
oungest affective relative [13,73]. The conﬁdence in the overall
ndoscopic resection has an impact on the surveillance intervals.
n annual colonoscopy is recommended in SSA polyposis. Given
SAs speciﬁc features, a piece-meal endoscopic mucosal resection
ustiﬁed an early follow-up colonoscopy within 6 months to 1 year
13,73].
. Conclusion
SSAs present endoscopic, pathological and molecular proﬁles
istinct from others polyps. Previously under-diagnosed, physi-
ians now identiﬁed SSAs. The serrated neoplastic pathway is
ccounting for up to one-third of all sporadic colorectal cancers and
SAs have been identiﬁed as the main precursor lesions in serrated
arcinogenesis. By analogy with the adenoma–adenocarcinoma
equence,  the SSAs–adenocarcinoma sequence, has been identi-
ed. The development of endoscopic resection techniques permits
he consideration of a non-surgical approach as the ﬁrst option
egardless of the size of the lesion. SSAs warrant the watchfulness
f physicians and require an optimal quality of the colonoscopy
rocedure, a thorough evaluation of the lesion, an adequate endo-
copic resection and follow-up colonoscopies in accordance with
SAs guidelines.
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